- Home
- MNPR vs DMB Comparison
MNPR vs DMB Comparison
Compare MNPR & DMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- DMB
- Stock Information
- Founded
- MNPR 2014
- DMB 2013
- Country
- MNPR United States
- DMB United States
- Employees
- MNPR N/A
- DMB N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- DMB Trusts Except Educational Religious and Charitable
- Sector
- MNPR Health Care
- DMB Finance
- Exchange
- MNPR Nasdaq
- DMB Nasdaq
- Market Cap
- MNPR 209.3M
- DMB 185.2M
- IPO Year
- MNPR 2019
- DMB N/A
- Fundamental
- Price
- MNPR $35.17
- DMB $10.20
- Analyst Decision
- MNPR Strong Buy
- DMB
- Analyst Count
- MNPR 6
- DMB 0
- Target Price
- MNPR $59.60
- DMB N/A
- AVG Volume (30 Days)
- MNPR 55.8K
- DMB 76.6K
- Earning Date
- MNPR 08-08-2025
- DMB 01-01-0001
- Dividend Yield
- MNPR N/A
- DMB 4.17%
- EPS Growth
- MNPR N/A
- DMB N/A
- EPS
- MNPR N/A
- DMB N/A
- Revenue
- MNPR N/A
- DMB N/A
- Revenue This Year
- MNPR N/A
- DMB N/A
- Revenue Next Year
- MNPR N/A
- DMB N/A
- P/E Ratio
- MNPR N/A
- DMB N/A
- Revenue Growth
- MNPR N/A
- DMB N/A
- 52 Week Low
- MNPR $1.72
- DMB $8.94
- 52 Week High
- MNPR $54.30
- DMB $11.79
- Technical
- Relative Strength Index (RSI)
- MNPR 51.51
- DMB 61.83
- Support Level
- MNPR $31.17
- DMB $10.04
- Resistance Level
- MNPR $35.01
- DMB $10.11
- Average True Range (ATR)
- MNPR 2.10
- DMB 0.08
- MACD
- MNPR 0.11
- DMB 0.02
- Stochastic Oscillator
- MNPR 46.49
- DMB 97.96
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About DMB BNY Mellon Municipal Bond Infrastructure Fund Inc.
BNY Mellon Municipal Bond Infrastructure Fund, Inc. is a diversified closed-end management investment company. The fund's investment objective is to provide as high a current income exempt from regular federal income tax as is consistent with the preservation of capital. It invests in transportation, energy and utilities, social infrastructure, and water and environmental sectors.